You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

CLINICAL TRIALS PROFILE FOR SHR3680

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for SHR3680

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02691975 ↗	A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients	Active, not recruiting	Jiangsu HengRui Medicine Co., Ltd.	Phase 1/Phase 2	This study evaluates the tolerability, safety, pharmacokinetics and efficacy of SHR3680 in patients with metastatic castration-resistant prostate cancer (mCPRC). All participants will receive SHR3680.
NCT02747342 ↗	A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer	Completed	Atridia Pty Ltd.	Phase 1	This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC).
NCT03520478 ↗	A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer	Active, not recruiting	Jiangsu HengRui Medicine Co., Ltd.	Phase 3	The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.
NCT03741712 ↗	A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC	Terminated	Jiangsu HengRui Medicine Co., Ltd.	Phase 1/Phase 2	The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
NCT03805399 ↗	FUSCC Refractory TNBC Umbrella (FUTURE)	Recruiting	Fudan University	Phase 1/Phase 2	This is a Phase Ib/II, open-label, umbrella study evaluating the efficacy and safety of multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping of patients' depends on FUSCC 500+ gene panel testing and IHC subtype staining.
NCT04102124 ↗	A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC	Active, not recruiting	Jiangsu HengRui Medicine Co., Ltd.	Phase 2	The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for SHR3680

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Prostate Cancer	5
Castration-resistant Prostate Cancer	3
Prostate Cancer Patients	2
Breast Neoplasm	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Prostatic Neoplasms	11
Breast Neoplasms	2
Hypersensitivity	1
Recurrence	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SHR3680

Trials by Country

Map
Table

Trials by Country for
Location	Trials
China	21
Poland	3
Czechia	2
Australia	2
Bulgaria	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SHR3680

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	4
Phase 1/Phase 2	3
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Recruiting	6
Active, not recruiting	4
Not yet recruiting	4
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SHR3680

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
Jiangsu HengRui Medicine Co., Ltd.	13
Fudan University	2
Atridia Pty Ltd.	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Industry	14
Other	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.